Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia

Current Topics in Medicinal Chemistry

Volumn 6, Issue 8, 2006, Pages 771-785

  Lindsley, Craig W ^a   Shipe, William D ^a   Wolkenberg, Scott E ^a   Theberge, Cory R ^a   Williams Jr , David L ^a   Sur, Cyrille ^a   Kinney, Gene G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Glutamate; Glycine; GlyT1; mGluR5; NMDA; NMDA hypofunction; Schizophrenia

Indexed keywords

ALX 5407; CP 802079; CYCLOSERINE; DE 10149370; DE 10315570; DEXTRO SERINE; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR AGONIST; GLYCINE; GLYCINE TRANSPORTER 1; GT 6006; METHYLPHENIDATE; MUSCARINIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; ORG 24598; PHENYLGLYCINE; PIPERIDINE DERIVATIVE; PROTEIN INHIBITOR; PYRROLIDINE DERIVATIVE; QUISQUALIC ACID; SARCOSINE; SEROTONIN UPTAKE INHIBITOR; SSR 504734; SSR 506204; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ALLOSTERISM; ATAXIA; BINDING SITE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; MOTOR DYSFUNCTION; NONHUMAN; POSITIVE SYNDROME; PROTEIN FUNCTION; PROTEIN TARGETING; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SYMPTOM; VALIDATION PROCESS; VOMITING;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BENZIMIDAZOLES; BRAIN; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; PHTHALIMIDES; PYRAZOLES; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SARCOSINE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 33646551184     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606777057599     Document Type: Review

References (111)

1. Andreasen, N.C. Schizophrenia: the fundamental questions. Brain Res. Rev. 2000, 31, 106-112.
2. Karayiorgou, M. Genetic aspects of schizophrenia. Clin. Neurosci. Res. 2001, 1, 158-163.
3. Meador-Woodruff, J.H.; Healy, D.J. Glutamate receptor expression in schizophrenic brain. Brain Res. Rev. 2000, 31, 288-294.
4. Lowe, John A. III Novel inhibitors of the type 1 transporter for glycine (GlyT1) as antipsychotic agents. Expert Opin. Ther. Patents 2005, 15, 1657-1662 and references therein.
5. Marino, P.J.; Conn, P.J. Direct and indirect modulation of the N-Methyl-D-Aspartate receptor: potential for the development of novel antipsychotic therapies. Curr. Drug Targets - CNS Neur. Disord. 2002, 1, 1-16.
6. Carlsson, A.: Lindqvist, M. Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 1963, 20, 140-144.
7. Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261, 717-719.
8. Seeman, P.; Lee, T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188, 1217-1219.
9. Bertolino, A.; Breier, A.; Callicott, J. H.; Adler, C.; Mattay, V. S.; Shapiro, M.; Frank, J. A.; Pickar, D.; Weinberger, D. R. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 1999, 22, 125-132.
10. Laruelle, M.; Abi-Dargham, A.; van Dyck, C. H.; Gil, R.; D'Souza, C. D.; Erdos, J.; McCance, E.; Rosenblatt, W.; Fingado, C.; Zoghbi, S. S.; Baldwin, R. M.; Seibyl, J. P.; Krystal, J. H.; Charney, D. S.; Innis, R. B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci.U.S.A. 1996, 93, 9235-9240.
11. Laruelle, M.; D'Souza, C. D.; Baldwin, R. M.; Abi-Dargham, A.; Kanes, S. J.; Fingado, C. L.; Seibyl, J. P.; Zoghbi, S. S.; Bowers, M. B.; Jatlow, P.; Charney, D. S.; Innis, R. B. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997, 17, 162-74.
12. Angrist, B.M. In Amphetamine and its analogues, Cho; Segals, Eds. Academic Press: San Diego, CA 1994, pp.387-414.
13. Casey, D. E. Side effect profiles of new antipsychotic agents. J Clin. Psy. 1996, 57 (Suppl 11) 40-5; discussion 46-52.
14. Hirsch, S.; Barnes, T.R.E. In Schizophrenia, Hirsch; Weinberger, Eds.; Blackwell Science: Oxford, UK, 1995; pp. 440-445.
15. Mohn, A.R.; Gainetdinov, R.R.; Caron, M. G.; Koller, B. H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98, 427-36.
16. Javitt, D.C.; Zukin, S.R. Recent advances in the phenylcyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148, 1301-1308.
17. Olney, J.W.; Farber, N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52, 998-1007.
18. Olney, J.W.; Newcomer, J.W.; Farber, N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatry Res. 1999, 33, 523-533.
19. Hashimoto, K.; Okamura, N.; Shimizu, E.; Iyo, M. Glutamate hypothesis of schizophrenia and approach for possible therapeutics. Curr. Med. Chem.: CNS Agent. 2004, 4, 147-154.
20. Borges, K.; Dingledine, R. AMPA receptors: molecular and functional diversity. Prog. Brain Res. 1998, 116, 153-70.
21. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7-61.
22. Lees, G. J. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 2000, 59, 33-78.
23. Yamakura, T.; Shimoji, K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog. Neurobiol. 1999, 59, 279-298.
24. Ikeda, K.; Nagasawa, M.; Mori, H.; Araki, K.; Sakimura, K.; Watanabe, M.; Inoue, Y.; Mishina, M. Cloning and expression of he epsilon 4 subunit of the NMDA receptor channel. FEBS Lett. 1992, 313, 34-8.
25. Ishii, T.; Moriyoshi, K.; Sugihara, H.; Sakurada, K.; Kadotani, H.; Yokoi, M.; Akazawa, C.; Shigemoto, R.; Mizuno, N.; Masu, M.; Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J. Biol. Chem. 1993, 268, 2836-43.
26. Kutsuwada, T.; Kashiwabuchi, N.; Mori, H.; Sakimura, K.; Kushiya, E.; Araki, K.; Meguro, H.; Masaki, H.; Kumanishi, T.; Arakawa, M.; Molecular diversity of the NMDA receptor channel. Nature 1992, 358, 36-41.
27. Monyer, H., Sprengel, R.; Schoepfer, R.; Herb, A.; Higuchi, M.; Lomeli, H.; Burnashev, N.; Sakmann, B.; Seeburg, P. H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992, 256, 1217-21.
28. Moriyoshi, K.; Masu, M.; Ishii, T.; Shigemoto, R.; Mizuno, N.; Nakanishi, S. Molecular cloning and characterization of the rat NMDA receptor. Nature 1991, 354, 31-37.
29. Ciabarra, A. M.; Sullivan, J. M.; Gahn, L. G.; Pecht, G.; Heinemann, S.; Sevarino, K. A. Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J. Neurosci. 1995, 15, 6498-6508.
30. Anantharam, V.; Panchal, R. G.; Wilson, A.; Kolchine, V. V.; Treistman, S. N.; Bayley, H. Combinatorial RNA splicing alters the surface charge on the NMDA receptor. FEBS Lett. 1992, 305, 27-30.
31. Yamazaki, M.; Mori, H.; Araki, K.; Mori, K.J.; Mishina, M. Cloning, expression and modulation of a mouse NMDA receptor subunit. FEBS Lett. 1992, 300, 39-45.
32. Suchanek, B.; Seeburg, P. H.; Sprengel, R. Gene structure of the murine N-methyl D-aspartate receptor subunit NR2C. J. Biol. Chem. 1995, 270, 41-44.
33. Mori, H.; Mishina, M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995, 34, 1219-1237.
34. Johnson, J.W.; Ascher, P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325, 529-531.
35. Johnson, J. W.; Ascher, P. Equilibrium and kinetic study of glycine action on the N-methyl-D-aspartate receptor in cultured mouse brain neurons. J. Physiol, 1992, 455, 339-365.
36. Anson, L. C.; Chen, P. E.; Wyllie, D. J.; Colquhoun, D.; Schoepfer, R. Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J. Neurosci. 1998, 18, 581-9.
37. Laube, B.; Hirai, H.; Sturgess, M.; Betz, H.; Kuhse, J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 1997, 18, 493-503.
38. Wood, M. W.; VanDongen, H. M.; VanDongen, A. M. An alanine residue in the M3-M4 linker lines the glycine binding pocket of the N-methyl-D-aspartate receptor. J. Biol. Chem. 1997, 272, 3532-3537.
39. Williams, K.; Chao, J.; Kashiwagi, K.; Masuko, T.; Igarashi, K. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit. Mol. Pharm. 1996, 50, 701-8.
40. Sur, C.; Kinney, G.G. The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin. Investig. Drugs 2004, 13, 515-521 and references therein.
41. Ferrer-Montiel, A. V.; Sun, W.; Montal, M. Molecular design of the N-methyl-D-aspartate receptor binding site for phencyclidine and dizolcipine. Proc. of the Natl. Acad. Sci. USA 1995, 9217, 8021-8025, and references therein.
42. Millan, M.J. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia. Curr. Drug. Target CNS Neurol. Disord. 2002, 1, 191-213.
43. Javitt, D.C.; Zylberman, I.; Zukin, S.R.; Heresco-Levy, U.; Lindenmayer, J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 1994, 151, 1234-1236.
44. Leiderman, E.; Zylberman, I.; Zukin, S.R.; Cooper, T.B.; Javitt, D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol. Psychiatry 1996, 39, 213-215.
45. Heresco-Levy, U.; Javitt, D.; Ermilov, M.; Mordel, C.; Horowitz, A.; Kelly, D. Double blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 1996, 169, 610-617.
46. Heresco-Levy, U.; Javitt, D.C; Ermilov, M.; Mordel, C.; Silipo, G.; Lichtenstein, M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 1999, 56, 29-36.
47. Heresco-Levy, U.; Ermilov, M.; Lichtenberg, P.; Bar, G.; Javitt, D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 2004, 55, 165-171.
48. Tsai, G.; Yang, P.; Chung, L.C.; Lange, N.; Coyle, J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 1998, 44, 1081-1089.
49. Liu, J.; Moghaddam, B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J. Pharm. Exp. Ther. 1995, 274, 1209-1215.
50. Malhotra, A. K.; Adler, C. M.; Kennison, S. D.; Elman, I.; Pickar, D.; Breier, A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry 1997, 42, 664-668.
51. Biel, J.H.; Nuhfer, P. A.; Hoya, W. K.; Leiser, H. A.; Abood, L. G. Cholinergic blockade as an approach to the development of new psychotropic agents. Ann. New York Acad. Sci. 1962, 96, 251-262.
52. Fisher, C. M. Visual hallucinations on eye closure associated with atropine toxicity. A neurological analysis and comparison with other visual hallucinations. Can. J. Neur. Sci. 1991, 18, 18-27.
53. Mego, D. M.; Omori, J. M.; Hanley, J. F. Transdermal scopolamine as a cause of transient psychosis in two elderly patients. South. Med. J. 1988, 81, 394-395.
54. Fisch R Z Trihexyphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia?. Acta Psychiatr. Scand. 1987, 75, 91-94.
55. Smith, J. M. Abuse of the antiparkinson drugs: a review of the literature. J. Clin. Psychiatry 1980, 41, 351-354.
56. Cohen, L.H.; Thale, T.; Tissenbaum, M.J. Arch. Neural. Psychiatry 1944, 51, 171.
57. Shannon, H. E.; Rasmussen, K.; Bymaster, F. P.; Hart, J. C.; Peters, S. C.; Swedberg, M. D.; Jeppesen, L.; Sheardown, M. J.; Sauerberg, P.; Fink-Jensen, A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr. Res. 2000, 42, 249-259.
58. O'Hara, P.J.; Sheppard, P.O.; Thogerson, H.; Venezia, D.; Haldeman, B.A.; McGrane, V.; Houamed, K.M.; Thomsen, C.; Gilbert, T.L.; Mulvihill, E.R. The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 1993, 11, 41-52.
59. Conn, P.J.; Pin, J-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237.
60. Bockaert, J.; Pin, J-P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 18, 1723-1729.
61. Dominguez, C.; Prieto, L.; Valli, M. J.; Massey, S. M.; Bures, M.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D.; Monn, J. A. Methyl Substitution of 2-Aminobicyclo[3.1.0] hexane 2,6-Dicarboxylate (LY354740) Determines Functional Activity at Metabotropic Glutamate Receptors: Identification of a Subtype Selective mGlu2 Receptor Agonist. J. Med. Chem. 2005, 48, 3605-3612.
62. Johnson, M.P.; Nisenbaum, E.S.; Large, T.H.; Emkey, R.; Baez, M.; Kingston, A.E. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlul, mGlu2 and mGlu5 potentiators and antagonists. Biochem. Soc. Transact. 2004, 32, 881-887.
63. Kew, J.N.C. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol. Therapeut. 2004, 104, 233-244.
64. Kew, J.N.C.; Kemp, J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005, 179, 4-29.
65. Williams, D.L. Jr.; Lindsley, C.W. Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Curr. Top. Med. Chem., 2005, 5, 825-846.
66. Lindsley, C.W.; Wolkenberg, S.E.; Shipe, W.; Williams, D.L. Jr. 'Recent Advances in Positive Allosteric Modulators of Metabotropic Glutamate Receptors (mGluRs)', Curr. Opin. Drug Discov. Dev., 2005, 8(4), 449-457.
67. Danysz, W.; Parsons, A.C. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic implications. Pharmacol. Rev. 1998, 50, 597-664.
68. Smith, K.E.; Borden, L.A.; Hartig, P.R.; Branchek, T.; Weinshank, R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 1992, 8, 927-935.
69. Borowsky, B.; Mezey, E.; Hoffman, B.J. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 1993, 10, 851-863.
70. Liu, Q.R.; Lopez-Corcuera, B.; Mandiyan, S.; Nelson, H.; Nelson, N. Cloning and expression of a spinal cord- and brain stem-specific glycine transporter with novel structural features. J. Biol. Chem. 1993, 268, 22802-22808.
71. Kim, K.-M.; Kingsmore, S.F.; Han, H. Cloning of the human glycine transporter Type 1: molecular and pharmacological characteriztion of novel isoform variants and chromosomal localization of the gene. Mol. Pharmacol. 1994, 45, 608-617.
72. Morrow, J.A.; Collie, I.T.; Dunbar, D.R.; Walker, G.B.; Shahid, M.; Hill, D.R. Molecular cloning and functional expression of the human glycine transporter GlyT2 and chromosomal locaization of the gene in the human genome. FEBS Lett. 1998, 439, 334-340.
73. Nelson, N. The family of Na+/Cl- neurotransmitter transporters. J. Neurochem. 1988, 71, 1785-1803.
74. Zarfa, F.; Gomeza, J.; Olivares, L.; Aragon, C.; Gimenez, C. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur. J. Neurosci. 1995, 7, 1342-1352.
75. Zafra, F.; Aragon, C.; Olivares, L.; Danbolt, N.C.; Giminez, C.; Storm-Mathisen, J. Glycine transporters are differentially expressed among CNS cells. J. Neurosci. 1995, 15, 3952-3969.
76. Supplisson, S.; Bergman, C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J. Neurosci. 1997, 17, 4580-4590.
77. Atkinson, B.N.; Bell, S.C.; De Vivo, M. et al., ALX 5407: a potent, selective inhibitor of of the hGlyT1 glycine transporter. Mol. Pharm. 2001, 60, 1414-1420.
78. Aubrey, K.R.; Vandenberg, R.J. N-(3-4'-fluorophenyl]-3-[4'phenylphenoxy] propyl) sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. 2001, 134, 1429-1436.
79. Kinney, G.G.; Sur, C. Glycine site modulators and glycine transporter-1 inhibitors as novel targets for therapeutic targets for the treatment of schizophrenia. Neurosci. Drug Disc. 2005, 3, 35-43 and references therein.
80. Slassi, A.; Egle, I. Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases. Expert Opin. Ther. Patents 2004, 14, 201-214.
81. Bergeron, R.; Meyer, T.M.; Coyle, J.T.; Greene, R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. USA 1998, 95, 15730-15734.
82. Berger, A.J.; Dieudonne, S.; Ascher, P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 1998, 80, 3336-3340.
83. Martina, M.; Gorfinkel, Y.; Halman, S.; Lowe, J.A.; Periyalwar, P.; Schmidt, C.J.; Bergeron, R. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J. Physiol. 2004, 557, 489-500.
84. Kinney, G.G.; Sur, C.; Burno, M.; Mallorga, P.J.; Williams, J.B.; Figueroa, D.J.; Wittman, M.; Lemaire, W.; Conn, J.P. The glycine transporter type 1 inhibitor N-(3-4'-fluorophenyl]-3-[4'phenylphenoxy]propyl) sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. 2003, 23, 7586-7591.
85. Javitt, D.C.; Sershen, H.; Hashim, A.; Lajtha, A. Reversal of phenylcyclidine-induced hyperactivity by glycine and the glycien uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997, 17, 202-204.
86. Le Pen, G.; Kew, J.; Alberati, D.; Borroni, E.; Heitz, M.P.; Moreau, J.L. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibtior. Biol. Psychiatry 2003, 54, 1162-1170.
87. Pinard, E.; Ceccarelli, S.M.; Stadler, H.; Alberati, D. Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperdines as a novel class of GlyT1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 349-353.
88. Ceccarelli, S.M; Pinard, E..; Stadler, H.; Alberati, D. Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperdines as GlyT1 antagonists with improved pharmacological profile. Bioorg. Med. Chem. Lett. 2006, 16, 354-357.
89. Dachary, E.; Dargazanli, G.; Estenne-Bouhtou, G.; Veronique, C. Preparation of N-[phenyl(piperidin-2-yl)methyl]benzamide derviatives, preparation thereof and use thereof in therapy. WO 013100, 2004.
90. Dachary, E.; Dargazanli, G.; Estenne-Bouhtou, G.; Veronique, C. Preparation of N-[phenyl(piperidin-2-yl)methyl]benzamide derviatives, preparation thereof and use thereof in therapy. WO 013101, 2004.
91. Dargazanli, G.; Estenne-Bouhtou, G.; Veronique, C. Preparation of N-[phenyl(alkylpiperidin-2-yl)methyl]benzamides as specific inhibitors of glycine transporters glyt1 and/or glyt2. WO 037782, 2005.
92. Dargazanli, G.; Estenne-Bouhtou, G.; Magat, P. Preparation of N-[phenyl(piperidin-2-yl)methyl]benzamides as specific inhibitors of glycine transporters glyt1 and/or glyt2. WO 037792, 2005.
93. Dargazanli, G.; Estenne-Bouhtou, G.; Magat, P., Marabout, P.; Roger, P. Derivatives of N-heterocyclylmethyl-benazmide, preparation method thereof and application of same in therapeutics. WO 037785, 2005.
94. Dargazanli, G.; Estenne-Bouhtou, G.; Medaisko, F.; Rakotoarisoa, N. N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation thereof and use thereof in therapy. WO 013101, 2004.
95. Depoortere, R.; Daraganzanil, G.; Estenne-Bouhtou, G.; Coste, A.; Lanneau, C.; Desvignes, C.; Ponceet, M.; Heaulme, M.; Santucci, V., Decobert, M.; Cudennec, A.; Voltz, C.; Boulay, D.; Terranova, J.P.; Stemmelin, J.; Roger, P.; Marabout, B.; Sevrin, M.; Vige, X.; Biton, B.; Steinberg, R.; Francon, D.; Alonso, R.; Avenet, P.; Oury-Donat, F.; Perrautt, G.; Griebel, G. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new antipsychotic. Neuropsychopharmacology 2005, 30, 1963-1985.
96. O'Hara, P.J.; Sheppard, P.O.; Thogerson, H.; Venezia, D.; Haldeman, B.A.; McGrane, V.; Houamed, K.M.; Thomsen, C.; Gilbert, T.L.; Mulvihill, E.R. The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 1993, 11, 41-52.
97. Conn, P.J.; Pin, J-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237.
98. Bockaert, J.; Pin, J-P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 18, 1723-1729.
99. Awad, H.; Hubert, G.W.; Smith, Y.; Levey, A.I.; Conn, P.J. Metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 2000, 20, 7871-7879.
100. Mannaioni, G.; Marino, M.J.; Valenti, O.; Traynelis, S.F.; Conn, P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J.Neurosci. 2001, 21, 5925-5934.
101. Pisani, A.; Gubellini, P.; Bonsi, P.; Conquet, F.; Picconi, B.; Centonze, D.; Bernardi, G.; Calabresi, P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106, 579-587.
102. Pisani, A.; Calabresi, P.; Centonze, D.; Bernardi, G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurons. Br. J. Pharmacol. 1997, 120, 1007-1014.
103. Kinney, G.G.; Burno, M.; Campbell, U.C.; Hernandez, L.M.; Rodriguez, D.; Bristow, L.J.; Conn, P.J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Therapeut. 2003, 306, 116-123.
104. Schoepp, D.D.; Jane, D.E.; Moon, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38, 1431-1476.
105. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Disc. 2002, 1, 198-210.
106. O'Brien, J.A.; Lemaire, W.; Chen, T-B.; Chang, R.S.L.; Jacobson, M.A.; Ha, S.N.; Lindsley, C.W.; Schaffhauser, H.J.; Sur, C.; Pettibone, D.J.; Conn, P.J.; Williams, D.L. Jr. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) Mol. Pharmacol. 2003, 64, 731-740.
107. O'Brien, J.A.; Lemaire, W.; Wittmann, M.; Jacobson, M.A.; Ha, S.N.; Wisnoski, D.D.; Lindsley, C.W.; Schaffhauser, H.J.; Rowe, B. Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J,; Williams, D.L.Jr. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain. J. Pharmacol Exp. Therapeut. 2004, 309, 568-577.
108. Kinney, G.G.; O'Brien, J.A.; Lemaire, W.; Burno, M.; Bickel, D.J.; Clements, M.K.; Chen, T-B.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J.; Williams, D.L.Jr. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol.Exp. Therapeut. 2005, 313, 199-206.
109. Lindsley, C.W.; Wisnoski, D.D.; Duggan, M.E.; Leister, W.H.; Hartman, G.D. Huff, J.R.; Williams, D.L.Jr.; O'Brien, J.A.; Lemaire, W.; Sur, C.; Pettibone, D.J.; Kinney, G.G.; Burno, M.; Tiller, P.R.; Smith, S. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 (mGluR5) that potentiate receptor function in vivo. J. Med. Chem. 2004, 47, 5825-5828.
110. Mannaioni, G.; Marino, M.J.; Valenti, O.; Traynelis, S.F.; Conn, P.J. Metabotropic glutamate receptors 1 and 5 differentially regulae CA1 pyramidal cell function. J. Neurosci. 2001, 21, 5925-5934.
111. Bessis, A-S.; Bonnet, B.; Le Poul, E.; Rocher, J-P.; Epping-Jordan, M. Preparation of piperidine derivatives as modulators of metabotropic glutamate receptors (mGluR5). WO 044797, 2005.